Babcock & Wilcox Enterprises, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Babcock & Wilcox Enterprises, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $222.91M | Apr 2, 2019 |
| FY2018 | Sep 30, 2018 | $294.96M | Apr 2, 2019 |
| FY2018 | Jun 30, 2018 | $291.34M | Apr 2, 2019 |
| FY2018 | Mar 31, 2018 | $253.18M | Apr 2, 2019 |
| FY2018 | Dec 31, 2017 | $330.26M | Apr 2, 2019 |
| FY2018 | Sep 30, 2017 | $356.87M | Apr 2, 2019 |
| FY2018 | Jun 30, 2017 | $306.23M | Apr 2, 2019 |
| FY2018 | Mar 31, 2017 | $348.07M | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | $379.98M | Feb 28, 2017 |
| FY2016 | Sep 30, 2016 | $410.96M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $587.68M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $581.04M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $587.45M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $609.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $710.87M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $566.32M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $859.11M | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $1.06B | Mar 30, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | ($74.87M) | Apr 2, 2019 |
| FY2018 | Sep 30, 2018 | $10.46M | Apr 2, 2019 |
| FY2018 | Jun 30, 2018 | ($41.07M) | Apr 2, 2019 |
| FY2018 | Mar 31, 2018 | ($24.17M) | Apr 2, 2019 |
| FY2018 | Dec 31, 2017 | $13.44M | Apr 2, 2019 |
| FY2018 | Sep 30, 2017 | $30.75M | Apr 2, 2019 |
| FY2018 | Jun 30, 2017 | ($69.59M) | Apr 2, 2019 |
| FY2018 | Mar 31, 2017 | $49.61M | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | ($848.0K) | Feb 28, 2017 |
| FY2016 | Sep 30, 2016 | $73.76M | Feb 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.16M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($59.92M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($197.21M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($22.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $30.89M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($10.32M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($121.97M) | Mar 8, 2022 |
| FY2018 | Dec 31, 2018 | ($233.40M) | Apr 2, 2019 |
| FY2018 | Sep 30, 2018 | ($105.69M) | Apr 2, 2019 |
| FY2018 | Jun 30, 2018 | ($265.77M) | Apr 2, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.74M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($6.34M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($20.07M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($1.15M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $19.42M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($1.74M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($29.38M) | Mar 8, 2022 |
| FY2018 | Dec 31, 2018 | ($137.67M) | Apr 2, 2019 |
| FY2018 | Sep 30, 2018 | ($45.15M) | Apr 2, 2019 |
| FY2018 | Jun 30, 2018 | ($137.35M) | Apr 2, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.80M | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $1.60M | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | $4.40M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.90M | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $3.78M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.61M | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $8.85M | Apr 2, 2019 |
| FY2016 | Dec 31, 2015 | $16.54M | Feb 28, 2017 |
| FY2016 | Dec 31, 2014 | $18.48M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $21.04M | Feb 25, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.48M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $124.54M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $134.94M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $152.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $151.76M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $141.75M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $151.07M | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $204.71M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $221.15M | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $217.08M | Apr 2, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.89M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($118.74M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($42.27M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($30.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($111.20M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | ($40.81M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($176.32M) | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | ($281.89M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($189.83M) | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $2.27M | Apr 2, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.77M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.21M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $9.80M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $13.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $6.68M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $8.23M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $3.80M | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $5.47M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $14.28M | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $22.45M | Apr 2, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $662.94M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $726.99M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $775.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $941.69M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $913.27M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $599.08M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $626.52M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $745.50M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.32B | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | $1.53B | Feb 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $794.48M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $976.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $943.78M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $854.64M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $930.05M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $921.46M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $1.02B | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.13B | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | $968.19M | Feb 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.54M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($283.76M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($200.96M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.57M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $33.15M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($332.08M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($296.36M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($286.13M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $182.10M | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | $552.15M | Feb 28, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.10M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $51.41M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $54.30M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $84.17M | Mar 31, 2025 |
| FY2022 | Dec 31, 2021 | $116.46M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $47.36M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $47.16M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $47.11M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $85.68M | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $163.09M | Apr 2, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.70B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($1.65B) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.57B) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.36B) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.32B) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($1.34B) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.34B) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($1.22B) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($492.15M) | Apr 2, 2019 |
| FY2016 | Dec 31, 2016 | ($114.68M) | Feb 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.46M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $26.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $65.34M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $76.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $224.87M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $57.34M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $43.77M | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $43.21M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $43.72M | Apr 2, 2019 |
| FY2018 | Dec 31, 2016 | $87.43M | Apr 2, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $183.33M | Mar 8, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 8, 2022 |
| FY2016 | Dec 31, 2016 | (2) | Feb 28, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 28, 2017 |
| FY2016 | Dec 31, 2014 | 0 | Feb 28, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 8, 2022 |
| FY2016 | Dec 31, 2016 | (2) | Feb 28, 2017 |
| FY2016 | Dec 31, 2015 | 0 | Feb 28, 2017 |
| FY2016 | Dec 31, 2014 | 0 | Feb 28, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 130.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 95.14M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 89.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 88.70M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 86.29M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 54.45M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 46.37M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 16.88M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 44.07M | Apr 2, 2019 |